Skip to main content
Caliway Biopharmaceuticals Co., Ltd. (TPE:6919)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
70.10
+0.60 (0.86%)
Nov 13, 2026, 1:30 PM CST

TPE:6919 Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
15.9838.0444.4338.9312.8212.34
Revenue Growth
-54.34%-14.40%14.13%203.68%3.90%19.22%
Gross Profit
11.3426.5230.7627.479.619.23
Operating Income
-1,116-707.22-717.14-513.47-319.62-230.73
Net Income
-611.32-351.92-588.83-488.46-286.16-224.29
Earnings Per Share
-0.40-0.23-0.41-0.39-0.24-0.24
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3,8274,8609,6693,7121,111594.91
Total Debt
230.56311.8720.4628.6836.78
Net Cash (Debt)
3,5964,8579,6573,6911,083558.13
Net Cash Growth
-44.77%-49.70%161.63%240.96%93.96%-
Net Cash Per Share
2.343.156.752.980.920.61

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-397.01-425.9-522.31-423.94-242.76-110.7
Capital Expenditures
-17.55-16.53-10-8.6-14.16-14.9
Free Cash Flow
-414.55-442.43-532.31-432.54-256.93-125.6
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
70.94%69.72%69.23%70.56%74.94%74.83%
Operating Margin
-6982.61%-1859.31%-1613.95%-1318.88%-2493.17%-1869.95%
Pretax Margin
-3825.99%-925.20%-1325.18%-1254.64%-2232.10%-1817.52%
Profit Margin
-3825.99%-925.20%-1325.18%-1254.64%-2232.10%-1817.76%
FCF Margin
-2594.50%-1163.16%-1197.97%-1111.01%-2004.12%-1017.90%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-64.85----
PS Ratio
6823.976316.212123.71604.64587.23-